title: Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (> or = 5 units): a randomized study.
abstract: BACKGROUND
  Autologous blood transfusion presents no infectious or immunologic side effects. The aim of this randomized study was to determine the impact of recombinant human erythropoietin (rHuEPO) on the donation of 5 units of autologous blood by nonanemic patients who were candidates for elective surgery with transfusion requirements of > or = 5 units.
  
  
  METHODS
  Starting on Day -35, 420 mL of blood was taken weekly. All patients received 200 mg of iron saccharose complex intravenously at each visit and six subcutaneous injections of rHuEPO (141 U/kg) or placebo between Days -21 and -7.
  
  
  RESULTS
  Of 50 patients, 45 completed the study (placebo, 21; rHuEPO, 24). Total red cell production was higher in the rHuEPO group (p = 0.001). Donation of 5 units was possible for 67 percent (placebo group) and 79 percent (rHuEPO group) of patients (p = 0.5). The mean number of blood units donated was 4.6 (placebo group) and 4.7 (rHuEPO group). More patients in the placebo group received allogeneic blood (9/21 [43%] vs. 6/23 [26%]), although the difference did not reach significance (p = 0.34).
  
  
  CONCLUSIONS
  In nonanemic patients donating 5 units of blood, rHuEPO associated with intravenous iron increased total red cell production. However, no difference was found between the rHuEPO and placebo groups with regard to the number of units of autologous blood donated of the number of patients receiving allogeneic blood transfusion.
authors.affiliation: Department of Medicine, Cantonal University Hospital, Geneva, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: de Pree
authors.forename: B
authors.initials: B
authors.lastname: Mermillod
authors.forename: P
authors.initials: P
authors.lastname: Hoffmeyer
authors.forename: P
authors.initials: P
authors.lastname: Beris
mesh_terms: D000740:Anemia / Q000517:prevention & control; D001804:Blood Transfusion, Autologous; D017024:Chemotherapy, Adjuvant; D004311:Double-Blind Method; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D010919:Placebos; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin